Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"
TESEO
Observational Epidemiological Study of Cancer-associated Thrombosis: Registry of Thrombosis & NEoplasia of SEOM (TESEO Study)
1 other identifier
observational
700
1 country
48
Brief Summary
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
48 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 4, 2018
CompletedFirst Submitted
Initial submission to the registry
February 19, 2019
CompletedFirst Posted
Study publicly available on registry
February 27, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
May 16, 2025
May 1, 2025
8 years
February 19, 2019
May 13, 2025
Conditions
Outcome Measures
Primary Outcomes (8)
Location of origin of the thromboembolytic event
Distribution in the number of patients according to the anatomical location affected by the thromboembolytic event.
Baseline
Vessel of origin of the thromboembolytic event
Distribution in the number of patients according to the type of vessel affected by the thromboembolytic event.
Baseline
Thromboembolytic event diagnosis type
Proportion of patients with incidental versus symptomatic thormboembolic events
Baseline
Primary tumor at the time of the thromboembolic event
Distribution of patients according to the organ affected by the primary tumor.
Baseline
Tumor-Node-Metastasis classification
Based on the American Joint Committee on Cancer 2018 Tumor-Node-Metastasis classification system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Baseline
Time between cancer diagnosis and thromboembolic event
Based on date on confirmed diagnosis of cancer (primary tumor) and date of thromboembolic event
Baseline
Patient situation at the last visit
Number of patients with rethrombosis, bleeding, other complications, tumor progression or death.
12 months
Characteristics of treatment administered for cancer
Based on the number of patients prescribed with chemotherapy, radiation therapy, hormonal therapy, erythropoietin, transfusions, surgery, catheter, etc.
Baseline
Eligibility Criteria
Cancer patients
You may qualify if:
- Over 18 years of age with a histologically confirmed diagnosis of malignant tumor.
- Venous or arterial thromboembolism episode, symptomatic or incidental, in the month prior or any time after the cancer diagnosis and in the three previous months to enrollment, confirmed with an imaging technique: Doppler echocardiography, computed tomography (CT) angiography, etc.
- Signing of informed consent.
You may not qualify if:
- Clinical diagnosis of thromboembolic event without radiological confirmation.
- Presenting a single episode of superficial thrombophlebitis without association with another thromboembolic event.
- Each patient will be recorded just once, and therefore a second thromboembolic event will be considered a rethrombosis and will be recorded as such. Patients with a rethrombosis and a previous thromboembolic event before the start of the study in each center will not be able to be included.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (48)
Hospital Virgen de los Lirios
Alcoy, Alicante, Spain
Hospital Universitario de Torrevieja
Elche, Alicante, Spain
Hospital Son Espases
Palma, Balearic Islands, Spain
Institut Català D'Oncologia (ICO) L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari Parc Taulí
Sabadell, Barcelona, Spain
Hospital De Sant Joan Despi Moissès Broggi
Sant Joan Despí, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital de Especialidades de Jerez de la Frontera
Jerez de la Frontera, Cádiz, Spain
Complejo Hospitalario Univ. de Santiago
Santiago de Compostela, La Coruña, Spain
Hospital de Fuenlabrada
Fuenlabrada, Madrid, Spain
Hospital Universitario de Móstoles
Móstoles, Madrid, Spain
Hospital Infanta Cristina
Parla, Madrid, Spain
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Complejo Hospitalario Universitario de A Coruña
A Coruña, Spain
Hospital Universitario San Juan de Alicante
Alicante, Spain
Hospital Univesitario Torrecárdenas
Almería, Spain
Complejo Hospitalario Universitario de Badajoz
Badajoz, Spain
Hospital Clínic Barcelona
Barcelona, Spain
Hospital de Barcelona
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital de Basurto
Bilbao, Spain
Hospital Universitario San Pedro de Alcántara
Cáceres, Spain
Hospital General Universitario de Ciudad Real
Ciudad Real, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital General Virgen de la Luz
Cuenca, Spain
Hospital General Universitario de Elche
Elche, Spain
Hospital Universitari Dr. Josep Trueta/Institut Català D'Oncología Girona
Girona, Spain
Hospital Universitario de Jaén
Jaén, Spain
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain
Hospital Universitario Lucus Augusti
Lugo, Spain
Hospital Central de la Defensa Gómez Ulla
Madrid, Spain
Hospital Fundación Jimenez Díaz
Madrid, Spain
Hospital MD Anderson Cancer Center Madrid
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Clínico San Carlos
Madrid, Spain
Hospital Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario la Princesa
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario Morales Meseguer
Murcia, Spain
Hospital Universitario Infanta Sofía
San Sebastián de los Reyes, Spain
Oncoavanze
Seville, Spain
Consorcio Hospital General Universitario de Valencia
Valencia, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
Hospital Álvaro Cunqueiro
Vigo, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Andres Muñoz, M.D.
Hospital General Universitario Gregorio Marañón, Madrid
- STUDY CHAIR
José Muñoz Langa, M.D.
Hospital Universitario y Politécnico La Fe, Valencia
- STUDY CHAIR
Alberto Carmona Bayonas, M.D.
Hospital Universitario Morales Meseguer, Murcia
- STUDY CHAIR
Paula Jiménez Fonseca, M.D.
Hospital Universitario Central de Asturias, Oviedo
- STUDY CHAIR
Pedro Pérez Segura, M.D.
Hospital Universitario Clínico San Carlos, Madrid
- STUDY CHAIR
Eva Martínez de Castro, M.D.
Hospital Universitario Marqués de Valdecilla, Santander
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 19, 2019
First Posted
February 27, 2019
Study Start
July 4, 2018
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
May 16, 2025
Record last verified: 2025-05